Ernexa Therapeutics (ERNAW) Non-Current Deffered Revenue (2010 - 2024)
Ernexa Therapeutics (ERNAW) reported Non-Current Deffered Revenue of $298000.0 for Q2 2024, up 19.2% on a YoY basis from $250000.0 in Q3 2023, and down 13.62% quarter-over-quarter from $345000.0 in Q1 2024.
Ernexa Therapeutics (ERNAW) Non-Current Deffered Revenue (2010 - 2024) Analysis & Trends
Ernexa Therapeutics has reported Non-Current Deffered Revenue for 13 years, with the latest figure at $298000.0 in Q2 2024.
- For the quarter ending Q2 2024, Non-Current Deffered Revenue rose 19.2% year-over-year to $298000.0; the trailing twelve-month figure through Jun 2024 stood at $298000.0 (up 19.2% YoY), and the FY2023 full-year result was $392000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q2 2024 stood at $298000.0, down from $345000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $392000.0 in Q4 2023, with the low at $1000.0 in Q1 2020.
- Historically, Non-Current Deffered Revenue has averaged $223500.0 across 3 years, with a median of $250000.0 in 2023.
- Annual changes were most pronounced in 2020 — Non-Current Deffered Revenue plunged 95.65% — and 2024, when it soared 38.0%.
- Ernexa Therapeutics' Non-Current Deffered Revenue stood at $2000.0 in 2020, then soared by 19500.0% to $392000.0 in 2023, then dropped by 23.98% to $298000.0 in 2024.
- The last three Non-Current Deffered Revenue figures came in at $298000.0 (Q2 2024), $345000.0 (Q1 2024), and $392000.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ernexa Therapeutics | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 298,000.00 |
| Mar 31, 2024 | 345,000.00 |
| Dec 31, 2023 | 392,000.00 |
| Sep 30, 2023 | 250,000.00 |
| Jun 30, 2023 | 250,000.00 |
| Mar 31, 2023 | 250,000.00 |
| Dec 31, 2020 | 2,000.00 |
| Mar 31, 2020 | 1,000.00 |
| Dec 31, 2019 | 2,000.00 |
| Sep 30, 2019 | 13,000.00 |
| Jun 30, 2019 | 17,000.00 |
| Mar 31, 2019 | 23,000.00 |
| Dec 31, 2018 | 30,000.00 |
| Jun 30, 2018 | 44,000.00 |
| Mar 31, 2018 | 50,000.00 |
| Dec 31, 2017 | 63,000.00 |
| Sep 30, 2017 | 231,000.00 |
| Jun 30, 2017 | 281,000.00 |
| Mar 31, 2017 | 326,000.00 |
| Dec 31, 2016 | 219,000.00 |